Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
September 08, 2020 08:30 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate
September 04, 2020 10:31 ET
|
Arcturus Therapeutics Holdings Inc.
Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination Clinical study remains on...
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
August 18, 2020 09:00 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
August 11, 2020 08:00 ET
|
Arcturus Therapeutics Holdings Inc.
Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) --...
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
August 10, 2020 16:01 ET
|
Arcturus Therapeutics Holdings Inc.
COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ...
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer
August 06, 2020 08:30 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
August 04, 2020 08:30 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 31, 2020 16:01 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of...
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
July 29, 2020 00:30 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of...
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
July 28, 2020 16:01 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of...